alizapride
Small moleculeexperimental
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
0
Phase 3
0
Phase 4
1
Earliest trial started Dec 12, 2012 (NCT01636947)
Timeline
No events for the selected filters.
Indications
Approved for
Studied for
Mechanism of action
- Dopamine D2 receptorANTAGONIST
DRD2 antagonist
Chemistry & pharmacology
Loading structure…
SMILES
C=CCN1CCCC1CNC(=O)c1cc2nn[nH]c2cc1OC- Mol. weight
- 315.38 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Racemic Mixture
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL290194 ↗
Also known as
- alizaprida
- alizaprida
- alizapride
- alizapride
- alizapride
- alizapride
- alizapride
- alizapride
- alizapride
- alizapride
- alizapride hcl
- alizapride hydrochloride
- alizapride hydrochloride
- alizapridum
- alizapridum
- litican
- litican
- litican
- ms 5080
- ms-5080
- n-((1-allyl-2-pyrrolidinyl)methyl)-6-methoxy-1h-benzotriazole-5-carboxamide
- n-(1-allyl-2-pyrrolidinylmethyl)-6-methoxy-1h-benzotriazole-5-carboxamide hydrochloride
- n-((allyl-1-pyrrolidinyl-2)-methyl)methoxy-2-azimido-4,5-benzamide
- plitican
- plitican
- plitican
- plitican
- superan
- superan
- vergentan
- vergentan
- vergentan
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01636947 | Phase 4 | Dec 12, 2012 | Merck |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Merck | For profit | 1 | 1 | 1 | 2012 |
1 organizations
Page 1 / 1